Human papillomavirus (HPV) is a group of 150 related viruses, 75 percent of which cause warts on the arms, chest, feet, and hands, and 25 percent of HPV types known as high-risk HPV cause genital cancer. Human papillomavirus testing is used to screen for a variety of cancers, including cervical cancer, vaginal cancer, vulvar cancer, and others. According to the Centers for Disease Control and Prevention (CDC), HPV infection is linked to 66 percent of cervical cancers, 79 percent of anal cancers, 55 percent of vaginal cancers, and 62 percent of oropharyngeal cancers in women in the United States. The human papillomavirus test has been approved by the FDA as a preliminary screening test for cervical cancer. Despite FDA approval, the test can only be used in conjunction with the Pap smear test – the gold standard test for cervical cancer screening.
The introduction of next-generation HPV testing techniques for identifying type 16 and 18 HPV in samples is expected to drive the growth of the human papillomavirus testing market during the forecast period. Human papillomavirus tests are classified into two types based on technology: DNA probe technology and RNA probe technology. The DNA probe technology segment is expected to lead the market due to the greater number of approved products for HPV testing that use DNA probes. The segment is expected to expand rapidly in the coming years.
Read More…